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The level of gonadal hormones to which the female brain is exposed considerably
changes across the menopausal transition, which in turn, is likely to be of great relevance
for neurodegenerative diseases and psychiatric disorders. However, the neurobiological
consequences of these hormone fluctuations and of hormone replacement therapy in
the menopause have only begun to be understood. The present review summarizes
the findings of thirty-five studies of human brain function, including functional magnetic
resonance imaging, positron and single-photon computed emission tomography studies,
in peri- and postmenopausal women treated with estrogen, or estrogen-progestagen
replacement therapy. Seven studies using gonadotropin-releasing hormone agonist
intervention as a model of hormonal withdrawal are also included. Cognitive paradigms
are employed by the majority of studies evaluating the effect of unopposed estrogen
or estrogen-progestagen treatment on peri- and postmenopausal women’s brain. In
randomized-controlled trials, estrogen treatment enhances activation of fronto-cingulate
regions during cognitive functioning, though in many cases no difference in cognitive
performance was present. Progestagens seems to counteract the effects of estrogens.
Findings on cognitive functioning during acute ovarian hormone withdrawal suggest a
decrease in activation of the left inferior frontal gyrus, thus essentially corroborating the
findings in postmenopausal women. Studies of the cholinergic and serotonergic systems
indicate these systems as biological mediators of hormonal influences on the brain.
More, hormonal replacement appears to increase cerebral blood flow in several cortical
regions. On the other hand, studies on emotion processing in postmenopausal women are
lacking. These results call for well-powered randomized-controlled multi-modal prospective
neuroimaging studies as well as investigation on the related molecular mechanisms of
effects of menopausal hormonal variations on the brain.
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BACKGROUND
The change in ovarian hormone levels to which the female brain
is exposed during the menopausal transition is likely relevant
for neurodegenerative diseases as well as psychiatric disorders.
However, the effects of the peri- and postmenopausal estradiol
level decline and hormone replacement therapy (HRT) on the
brain have only begun to be understood (Mueller et al., 2014).
Undeniably, a substantial lack of agreement on the beneficial
vs. detrimental effect of HRT on mental health, and concerns
about potential adverse effects exist (Henderson and Greicius,
2010). Thus, the prevention and clinical management of men-
tal health problems during the menopausal transition suffers
from uncertainty, which renders research in this field of outmost
importance.
During the last two decades menopause researchers have
opted for an intermediate phenotype-based approach to fur-
ther the psychobiological dissection of menopausal hormonal
transition and HRT effects on mental health. Indeed, intermedi-
ate phenotypes (e.g., biochemical, endocrine, anatomical, phys-
iological) represent quantifiable basic biological or behavioral
processes, which are expected to be closer to the genetic under-
pinning as well as to the psychological functions that might be
affected (Meyer-Lindenberg and Weinberger, 2006; Rasetti and
Weinberger, 2011). Neuroimaging techniques are certainly suit-
able tools for investigating potential intermediate phenotypes
related to the neurobiological correlates of menopause and HRT.
The present review summarizes the findings of studies of
human brain function (i.e., functional magnetic resonance imag-
ing (fMRI), positron emission tomography (PET), single-photon
emission computed tomography (SPECT/SPET), and magnetic
resonance spectroscopy (MRS), of perimenopausal and post-
menopausal women treated with unopposed estrogen or com-
bined estrogen-progestagen replacement therapy. Additionally,
studies of gonadotropin-releasing hormone (GnRH) agonist
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treatment, as a pharmacological model of menopause, are also
considered.
STATE-OF-THE-ART
To date, 35 functional neuroimaging studies have investigated
brain function in peri- and postmenopausal women, and seven
additional studies have used GnRH agonist intervention as a
model of menopause (Tables 1–6). However, all studies are sta-
tistically under-powered since they include small samples, and
they are also characterized by high heterogeneity in terms of
study design. Differences regarding the study designs include:
controlled randomization vs. cross-sectional trials, parallel vs.
cross-over design, baseline vs. placebo control state, duration
of the HRT use, unopposed estradiol vs. combined estrogen-
progestagen therapy, route of administration and posology/dose
of HRT, time between menopause and start of HRT (“criti-
cal window”), and chronological and reproductive age of the
women. Dissimilarities regarding the neuroimaging data regard:
neuroimaging techniques, neuropsychological paradigms within
a cognitive domain, and statistical approaches for neuroimaging
data processing and analysis. All together, these factors impeded
any meta-analytical statistics.
COGNITIVE FUNCTIONING
The great majority of studies evaluating the effect of unopposed
estrogen or combined estrogen-progestagen treatment on the
menopausal and postmenopausal brain used cognitive paradigms
(Tables 1, 2). Longitudinal, randomized controlled trial stud-
ies of the effects of estrogen treatment—three to twelve weeks
in duration—indicated a higher activation of fronto-cingulate
regions during cognitive functioning (Table 1), as assessed by
fMRI using verbal, non-verbal and spatial working memory tasks.
However, in spite of higher activation in fronto-cingulate regions,
no differences in working memory performance were noted
(Shaywitz et al., 1999; Joffe et al., 2006; Dumas et al., 2010). One
sample of healthy postmenopausal women with an average of 7
years of prior estrogen use, and randomly assigned to a placebo
or three-month hormonal treatment, showed an estradiol, mem-
ory load-dependent, effect on frontal activation, with a greater
modulatory effect during the more difficult visual verbal work-
ing memory task (Dumas et al., 2010). During a verbal memory
task, inferior frontal and posterior parietal regions, and dur-
ing a spatial working memory task, frontal, posterior cingulate,
and parietal regions, activation was greater in peri- and post-
menopausal women receiving a three-week transdermal estradiol
treatment compared to placebo (Joffe et al., 2006). Besides an
increased and decreased inferior frontal lobule activation during
storage of verbal and non-verbal material, respectively, a relatively
large, randomized, double-blind, placebo-controlled, cross-over
trial of estrogen treatment (for three weeks) in perimenopausal
women indicated also a sharpened hemisphere encoding retrieval
asymmetry (HERA) effect, with higher left-frontal hemisphere
activation during encoding, and higher right-frontal hemisphere
activation during retrieval in a working memory task (Shaywitz
et al., 1999).
Moreover, two randomized controlled fMRI trials (Table 1),
with cross-over designs, including ten healthy postmenopausal
women each, suggested a counteractive effect of progestagens on
memory, with increased, but to a lesser extent, prefrontal cor-
tex activation after four weeks of combined estrogen-progestagen
treatment vs. placebo (Smith et al., 2006; Persad et al., 2009). On
the contrary, one parallel study of postmenopausal women did
not observe any effect of six months of combined hormonal treat-
ment in comparison with placebo on verbal fluency and mental
rotation (Davison et al., 2013).
Results of cross-sectional neuroimaging studies on cognitive
function are sparse (Table 2), and interpretation is limited by
sample selection and study set-up discrepancies (Gleason et al.,
2006; Berent-Spillson et al., 2010, 2012; Maki et al., 2011).
Combined estrogen- or estrogen-progestagen treatment was asso-
ciated with increased bilateral activation of the medial temporal
lobe during encoding in postmenopausal women (Gleason et al.,
2006). Activation in the medial temporal lobe during verbal and
figural memory tasks differed between postmenopausal women
who started HRT before menopause and never users, with a more
pronounced decrease in parahippocampal gyrus and increase
in left hippocampus activation in the HRT users during verbal
recognition (Maki et al., 2011). Furthermore, HRT was associated
with a better verbal memory performance, indicating a benefi-
cial effect of HRT (Maki et al., 2011). A relatively large study
found generalized increased brain activation upon a visual work-
ing memory task in women who had used estrogen, with or
without progestagen addition, for more than 10 years, and begun
HRT within two years of the menopause, compared to non-
users (Berent-Spillson et al., 2010). In the same sample, activation
of the medial temporal lobes correlated positively with perfor-
mance during a visual working memory task (Berent-Spillson
et al., 2010). Moreover, differences between pre-, peri-, and post-
menopausal women during a verbal, but not visual, memory
task were found, independently of age, in frontal, prefrontal, and
temporal cortices, with brain region activation being negatively
correlated with estrogen levels (Berent-Spillson et al., 2012).
Finally, Maki and Resnick’s longitudinal PET study provided
evidence that estrogen treatment, with or without progestagen
addition, modulates longitudinal changes in blood flow in brain
regions implicated in cognitive function. Firstly, HRT users and
non-users performing a verbal memory and a visual memory
task showed, in a complex fashion, differences in the activation
of regions subserving memory, such as the frontal lobe (Resnick
et al., 1998). A smaller and overlapping sample was investigated
two years later using the same study set-up. Greater activation
of the temporal gyrus, hippocampus and insula regions, and the
parahippocampal gyrus and inferior frontal gyrus, was observed
during verbal and visual memory tasks, respectively, in long-term
HRT users (more than two years) compared to non-users, thus
indicating altered blood flow in brain areas subservicing mem-
ory in the presence of HRT (Maki and Resnick, 2000). However,
in non-users other regions were also activated during the figu-
ral memory task compared to users (Maki and Resnick, 2000).
Moreover, HRT was associated with better memory performance
in the neuropsychological tests at both time points (Resnick et al.,
1998; Maki and Resnick, 2000).
Notably, different components of the cognitive tasks con-
tribute to the complexity of the many neuropsychological
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functions examined (Tables 1, 2). Functional domains of mem-
ory, such as executive function, attention, visuospatial processing,
and language, are subserved by different brain circuits, which
may have variable sensitivity to specific interventions (Gibbs,
2010). Memory tasks have been used predominantly to assess
menopausal and HRT effects on cognitive functioning. Working
memory, mainly subserved by the dorsal prefrontal cortex in
humans, is a limited-capacity storage system to maintain and
manipulate information over short time periods and is critical
for many daily activities (Gibbs, 2010). The visual-verbal N-back
test of working memory, used by Dumas et al. (2010), allows
the examination of different working memory loads (i.e., 0-, 1-,
2-, and 3- back conditions), from a condition of minimal mem-
ory load (0-) to one where subjects need to hold four letters in
memory and update working memory as the next letter appears,
alternatively seen as a cognitive stress model. Other verbal mem-
ory tasks, used by Shaywitz et al. (1999), Joffe et al. (2006), Persad
et al. (2009), Berent-Spillson et al. (2012), Davison et al. (2013),
involve learning and recall of word lists. Verbal memory has been
suggested to be themost sensitive cognitive domain to the effect of
HRT, and also a candidate proxy for dementia (Maki, 2013). The
obvious discrepancy between imaging and cognition test results
might be due to compensatory or deficient mechanisms, but also
to differences in neuropsychological test performance within or
outside the scanner. Noticeably estrogen did not seem to equally
affect all cognitive domains, as shown by experimental studies
(Gibbs, 2010).
fMRI detects changes in the blood oxygen level dependent
(BOLD) signal, which is an index of the metabolic expenditures
by neurons or glia during and immediately after the task. The
BOLD signal is commonly accepted to reflect changes in neural
activity, but interpretation should be cautious (Henderson and
Greicius, 2010). Overall, it seems plausible to conclude that estro-
gen, alone or in combination with progestagens, positively affects
brain activation during memory processing in postmenopausal
women (Tables 1, 2). Nevertheless the neural underpinnings
of HRT effects on memory remain to be elucidated. The pre-
frontal cortex is of particular relevance for cognition, and the
neural substrate of the estradiol-induced memory enhancement,
possibly due to its sensitivity to the hormonal milieu. Future
studies are needed to clarify whether HRT may lower the risk
of Alzheimer’s disease and protect against age-related declines
in memory (Henderson and Greicius, 2010; Marjoribanks et al.,
2012), as well as which duration and timing of HRT would be
optimal (Daniel, 2013).
Pharmacological menopause and cognitive functioning
Gonadotropin-releasing hormone agonist (GnRHa) treatment
has been used as a model for menopause to assess cognitive sig-
natures in young women (Table 3). GnRH is produced by the
hypothalamus and pulsatile secretion of GnRH causes the ante-
rior pituitary to release follicle-stimulating hormone (FSH) and
luteinizing hormone (LH). Continuous treatment with GnRHa,
on the other hand, will result in suppressed gonadal hor-
mone production and is commonly prescribed for endometriosis,
advanced breast cancer, but also to facilitate and secure subse-
quent safe super-ovulation during assisted reproduction therapy.
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GnRHa treatment results in postmenopausal levels of endoge-
nous estradiol by the second to fourth week of administration.
Berman and colleagues performed a seminal PET study using a
GnRHa-induced hypogonadismmodel in 1997, and found higher
blood flow in the inferior frontal gyrus during estrogen- or pro-
gestagen add-back to the GnRHa treatment (Berman et al., 1997).
Three subsequent fMRI studies from Craig et al., though region-
of-interest based, indicated a decreased activation of the same
region, i.e., the left inferior frontal gyrus, during different mem-
ory tasks, after 8 weeks of pharmacological menopause (Craig
et al., 2007b, 2008a,b). Moreover, this effect was demonstrated
to be reversible as reflected at re-examination six months after
discontinuation of GnRHa treatment (Craig et al., 2008b). Also,
restored cognitive performance has been observed after GnRHa
resolution (Craig et al., 2008b), or GnRHa discontinuation plus
estrogen add-back treatment (Sherwin and Tulandi, 1996).
These results essentially corroborate the neuroimaging find-
ings on working memory (i.e., visual, encoding and recogni-
tion, verbal and retrieval memory) in postmenopausal women
(Tables 1–3). It is likely that these effects are not a direct con-
sequence of the GnRHa but rather an indirect effect of reduced
estradiol and progesterone levels in the brain. However, though
the pseudo menopause produced by GnRHa is a powerful model,
the impact of short-term ovarian suppression on cognition in
young premenopausal women seems to be contradictory; in some
cases strong (Sherwin and Tulandi, 1996; Grigorova et al., 2006),
and in other cases only marginal (Rocca et al., 2014) or absent
(Owens et al., 2002).
Taken together, though limited by a region-of-interest analysis
approach, pharmacological challenge that induced acute ovarian
hormone suppression in premenopausal women leads to atten-
uation of the brain activation pattern in the left inferior frontal
gyrus (Table 3), a region sub-serving deep processing of to-be-
learned words, language and memory, typically activated during
performance of executive function tasks in healthy women.
NEUROBIOLOGICAL FUNCTIONING
Neurotransmitter systems
The changes in the hormonal milieu, and particularly in estro-
gen levels, during the menopausal transition period are likely
to modulate neurotransmitter and neuroendocrine systems,
thus modifying intermediate phenotypic patterns. Such neuro-
psycho-biological signatures may be involved in the mechanisms
by which hormone changes may elicit cognitive dysfunction
(Epperson et al., 2013), mental distress, and mental disorders
(Hafner et al., 1993; Hafner, 2003; Freeman et al., 2006, 2014;
Riecher-Rössler and Kulkarni, 2011). Most likely, the hormonal
effects on brain function highlighted by fMRI studies are indi-
rectly mediated through hormonal actions on neural sites serving
multiple neurobiological systems (e.g., cholinergic, serotoner-
gic, noradrenergic, and dopaminergic neurotransmitter system),
as indicated by studies of primates showing estrogen-mediated
neurotransmitter activities in the prefrontal cortex via alter-
ation of cholinergic and monoaminergic innervations (Voytko
et al., 2009), and emphasized by the widespread distribution
of estrogen and progesterone receptors in the brain (Brinton
et al., 2008; Wharton et al., 2012). The cholinergic, serotonergic,
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and dopaminergic systems have, in fact, been preliminarily
investigated in relation to menopause, and seem to be biological
mediators of positive effects of estrogens (Table 4) (Henderson
and Greicius, 2010).
Acetylcholine (ACh). The central cholinergic system is critically
involved in memory, learning and attention. Physiological aging
is associated with reduction in cholinergic functional markers,
such as choline acetyltransferase (ChAT), the enzyme synthetizing
ACh, but with a relative preservation of cholinergic cells and ter-
minals. Alzheimer’s disease, on the other hand, is associated with
drastic reductions in ChAT and diffuse degeneration of choliner-
gic terminals as well as loss of acetylcholine nicotinic and mus-
carinic receptors m1 and m4 (Gibbs, 2010; Chopra et al., 2011).
Both estrogen receptors have been identified in the nuclei of the
human basal forebrain, which is the source of major cholinergic
innervations to the cerebral cortex, hippocampus, and hypothala-
mus (Gibbs, 2010). Moreover, decreased cholinergic axon density
in the prefrontal cortex was found in ovariectomized monkeys
compared to estrogen-only or estrogen-progesterone treated ani-
mals, as well as to control animals (Kritzer and Kohama, 1999);
and cholinergic fiber density in the prefrontal, but not pari-
etal, cortex of ovariectomized monkeys is preserved after two
years of estrogen treatment (Tinkler et al., 2004). Estrogen is
indeed known to provide neurotrophic support, possibly through
synergistic actions with the cholinergic system, and to regulate
acetylcholine release, as supported by findings in rodents and
non-human primates (Voytko et al., 2009; Daniel, 2013). Thus,
while low menopausal estradiol levels are likely to diminish, HRT
may enhance the survival or plasticity of cholinergic cells in
postmenopausal women.
A cross-sectional PET study of women who initiated HRT
within 2 years of menopause, and who had used it for more
than 10 years, indicated a higher cholinergic activity (8–10%),
measured as acetylcholinesterase (AChE), the enzyme degrad-
ing ACh into choline and acetate, bilaterally in the posterior
cingulate of combined estrogen-progestagen users compared to
non-users (Smith et al., 2011). No effect on AChE was observed
in the estrogen-only users compared to the non-users (Smith
et al., 2011), suggesting a critical role of progesterone. On the
contrary, cholinergic synaptic terminal density, assessed as bind-
ing of acethylcoline transporter (VAChT) in a SPECT cross-
sectional study, was 25% higher in the parietal cortex of women
treated with estrogen-only, whom initiated HRT within 2 years
of menopause, compared to combined hormone users (Smith
et al., 2001). Moreover, VAChT binding in frontal, temporal
and parietal cortices, as well as anterior and posterior cingu-
late regions, was positively correlated with duration of HRT
use (Smith et al., 2001), consistent with a longer exposure to
gonadal steroids being associated with trophic support of cholin-
ergic neurons. Within the cholinergic system, receptors have also
been investigated using SPECT in a cross-sectional study, and
higher acethylcoline muscarinic receptor m1/m4 binding was
observed in postmenopausal estrogen users compared to women
not receiving hormonal therapy, with greater density in the hip-
pocampus, prefrontal cortex, striatum and thalamus (Norbury
et al., 2007).
Additional proof of an interaction between estrogens and
the cholinergic system has been given by two pharmaco-fMRI
studies by Craig and colleagues (Table 3). This is in line with
a protective effect of estrogen from the detrimental effects of
anti-ACh challenge on attention found in humans (Dumas et al.,
2006, 2008), monkeys (Voytko, 2002), and rodents (Sherwin and
Henry, 2008). The former study demonstrated an additive effect
of anticholinergic challenge with scopolamine on the decreased
inferior frontal gyrus activation during encoding and recognition
memory processing, in young women exposed to pharmacolog-
ical menopause compared to placebo (Craig et al., 2009). The
latter study, also using the cholinergic muscarinic receptor antag-
onist scopolamine, assessed visual working memory, and found
more pronounced reduction of activation in frontal regions and
parahippocampal gyrus in young women with pharmacologically
induced menopause (Craig et al., 2010). Moreover, three-month
estrogen treatment was shown to alter anticholinergic-related
(i.e., both with the antimuscarinic drug scopolamine and with
the antinicotinic drug mecamylamine) brain activation during
a working memory task in postmenopausal women (Dumas
et al., 2012b). Scopolamine challenge blocks muscarinic cholin-
ergic receptors, and contributes to impairment of encoding of
new memories; thus can be used as a pharmacological model
of cognitive decline to investigate HRT-by-cholinergic interactive
effects.
Altogether these studies reported an enhanced cholinergic
neurotransmission in the presence of HRT, however discor-
dantly regarding estrogen-only vs. estrogen-progestagens com-
bined treatment (Tables 3, 4). The paucity and conflicting nature
of findings regarding a modulatory effect of estrogen and/or
progestagens on the effects of age on neural integrity in brain
regions involved in cognitive function, on age-related memory
decline, and on risk for Alzheimer’s disease, impede any con-
clusion (Marjoribanks et al., 2012; Maki, 2013). Furthermore,
the effect of menopausal stage at HRT initiation on cholinergic
function and related hippocampus-mediated cognitive function-
ing needs to be explored (Daniel, 2013). For example short-, but
not long-, term hormonal treatment has been shown to enhance
cholinergic function in the prefrontal cortex and hippocampus of
ovariectomized rats (Gibbs, 2000).
Serotonin (5-HT). Effects of menopausal changes in hormonal
milieu and HRT may be partly mediated via the serotonin path-
way, as experimental animal models indicate effects of ovarian
hormones on the serotonergic system (Bethea et al., 2009; Voytko
et al., 2009; Sanchez et al., 2013). Three longitudinal, but small,
PET studies assessing the serotonin receptor 2A (5-HT2A) high-
lighted a general increased HRT-mediated binding potential in
frontal and cingulate regions in postmenopausal women com-
pared to baseline (Table 4) (Moses et al., 2000; Kugaya et al.,
2003; Moses-Kolko et al., 2003). Consistently, 5-HT2A recep-
tor availability in the prefrontal cortex was higher after two
months of unopposed estrogen use in two independent sam-
ples of postmenopausal women (Kugaya et al., 2003; Moses-
Kolko et al., 2003). Combined estrogen-progestagen treatment
for one month was associated with increased 5-HT2A binding
potential in the frontal, precentral, cingulate, lingual, fusiform,
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parahippocampal and temporal gyrus, mainly in the left hemi-
sphere, as well as in the insula, cuneus, and temporal pole in
one study of five postmenopausal women (Moses-Kolko et al.,
2003), and in the pregenual and dorso-anterior cingulate cortex,
dorsolateral and lateral orbito prefrontal cortex, bilaterally, based
on a region-of-interest approach, in another study of five post-
menopausal women (Moses et al., 2000). Further support for a
positive coupling between absolute levels of estradiol and global
5-HT2A receptor availability comes from a large cross-sectional
molecular imaging study in males (Frokjaer et al., 2010). Lastly,
one SPECT study indicated lower hippocampal 5-HT2A recep-
tor binding to be coupled with estrogen treatment in long-term
oophorectomized women, hypothesizing a down-regulation of
post-synaptic receptors due to increased activity of the serotoner-
gic pathway. However this result did not remain significant after
correction for multiple comparison (Compton et al., 2008), and
no firm conclusion can be derived from this finding due to the
lack of correction formultiple comparisons and the low test-retest
in the region of interest (Haugbol et al., 2007).
The mechanism by which HRT leads to a globally distributed
5HT2A binding increase is not fully understood. Yet, it potentially
involves hormone-mediated genomic as well as neurotrophic
mechanisms. Indeed, rodent work support that 5-HT2A gene
transcription is affected by estradiol. In ovariectomized rats,
two-week estrogen plus progesterone, however not estrogen-only,
treatment was associated with increased 5-HT2A mRNA in the
ventral hippocampus but not in the frontal cortex (Birzniece et al.,
2002). Likewise, at the protein level, 5-HT2A binding in the cere-
bral cortex of rats was increased after two-week estrogen-only, but
not combined estrogen-progesterone, treatment (Biegon et al.,
1983), while in blood of depressed women was decreased after
four months of hormonal treatment (Wihlback et al., 2001).
Additionally, reduced 5-HT2A mRNA and binding in the frontal
cortex of rats was restored after a two-week estrogen treatment
(Cyr et al., 1998), suggesting that hormonal withdrawal per se
also affects 5-HT2A receptor numbers. All together these findings
are in line with rat studies reporting direct effects of estradiol in
maintaining 5-HT2A receptor levels, both after castration of male
animals and after ovariectomy in female animals (Sumner and
Fink, 1997, 1998; Sumner et al., 1999, 2007). Testosterone, also
increase 5-HT2A receptor expression, however only when con-
verted to estradiol locally by aromatase (Sumner and Fink, 1998),
again highlighting that estradiol is the main driver of 5HT2A
responses to HRT.
A recent randomized placebo controlled study of post-
menopausal women found no effect of 8 weeks of HRT, of
neither estrogen-only nor combined estrogen-progestagen treat-
ment, on 5-HT1A binding potential (Table 4) (Kranz et al., 2014).
However, 5-HT1A receptor binding was negatively correlated at
the whole brain level with progesterone, but not estradiol, serum
concentrations in postmenopausal women (Stein et al., 2014).
Interestingly, an animal model of surgical menopause indicated a
time-dependent effect of estrogen on this autoreceptor, with one-
month, but not five-months, estrogen treatment being associated
with decreased 5-HT1A receptor protein expression in ovariec-
tomized monkeys in the dorsal raphe nucleus, which is source
of serotonergic neurons within CNS (Henderson and Bethea,
2008). However, combined estrogen plus progesterone admin-
istration decreased 5-HT1A receptor protein expression at both
time points (Henderson and Bethea, 2008). Also, 5-HT1A receptor
binding in the dorsal raphe nucleus has been shown to decrease
after one month of treatment with either estrogen, progesterone,
or a combination of both in ovariectomized monkeys (Lu and
Bethea, 2002). Thus, an enhanced time-dependent effect of HRT
on serotonergic neurotransmission cannot be excluded.
Additionally, using a dietary tryptophan depletion chal-
lenge, by which serotonergic tonus can be lowered transiently,
serotonin-by-estrogen interaction effects were found in a small
fMRI study in relation to cognitive and emotional processing
in early postmenopausal women (Table 4). When tryptophan
depleted, non-users had reduced bilateral dorsal lateral prefrontal
cortex and middle frontal/cingulate gyrus activation in compari-
son to estrogen-only treated women; while lowered orbitofrontal
cortex and amygdala activation in relation to emotion identifica-
tion was observed in the estrogen users (Epperson et al., 2012).
However, no interactive effect was observed between trypto-
phan or tyrosine/phenylalanine depletion and estrogen treatment
on emotional, behavioral, and cognitive performance in healthy
postmenopausal women (Newhouse et al., 2008, 2010). Women
exhibited increased stress-triggered negative mood and wors-
ened cognitive performance after a three-month estrogen admin-
istration compared to placebo, independently of monoamine
depletion (Newhouse et al., 2008, 2010).
Estrogen, alone or combined with progesterone, not only
modulates serotonergic function at the level of neurotransmitter
synthesis, turnover, release, and receptor, but has also a neu-
roprotective role on serotonin neurons, as indicated by studies
of monkeys (Bethea et al., 2009). The serotonin system criti-
cally modulates brain functions related to both cognition and
mood, thus it is plausible to hypothesize a synergistic effect of
estrogen and serotonin on cognitive functioning, emotion pro-
cessing, and affective regulation (Bethea et al., 2009). Indeed,
selective serotonin re-uptake inhibitors are valid alternatives to
estradiol for treatment of vasomotor symptoms, i.e., hot flashes,
and depressive symptoms (Al-Safi and Santoro, 2014; Joffe et al.,
2014). Future studies, ideally translational, must elucidate how
the serotonin system integrates sex-steroid hormone informa-
tion. In particular, the relative contributions from increases and
decreases in sex-steroid levels, pre- and postsynaptic receptor
involvement, and the timing of the responses, are warranted
to advance our understanding of how changes in sex-hormone
milieu may trigger cognitive dysfunction, depressive symptoms
and mental disorders.
Dopamine. Estrogens, alone and in combination with proges-
terone, are likely to affect the dopaminergic system too as findings
in non-human primate suggest an effect, although scattered and
less prominent, of estrogen on the dopaminergic system (Voytko
et al., 2009). To date one sole neuroimaging study has investigated
the dopaminergic system in thirteen healthy postmenopausal
women, reporting that dopamine transporter (DAT) availabil-
ity in women was increased in the left anterior putamen after
4 weeks of estrogen-only treatment, and in the anterior puta-
men after 2 weeks of combined estrogen-progestagen treatment
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(Gardiner et al., 2004). Beside this study, long-term estrogen ther-
apy has been reported to enhance dopaminergic responsivity to
apomorphine in postmenopausal women (Craig et al., 2004), but
further studies are needed.
Other neurochemical markers
MRS studies, through the detection of several metabolites (e.g.,
choline and N-acetyl aspartate), provide proxy measures of neu-
ral integrity of the brain, neuronal/glial membrane turnover and
function in menopause (Table 4). Never-treated postmenopausal
women were shown to have higher Choline (Cho)-containing
compounds in the parietal lobe and hippocampus, previously
identified as regions-of-interest, compared to women on HRT,
and long-term visual memory was negatively correlated with Cho
in the hippocampus (Robertson et al., 2001). Young women after
8 weeks of induced ovarian suppression with a GnRH agonist had
higher Cho, and Cho to creatine (Cr) ratio, in the left dorsolat-
eral prefrontal cortex (dlPFC), and borderline significant in the
left hippocampus (Table 3) (Craig et al., 2007a). The Cho MRS
peak mainly reflects the total amount of free acetylcholine, glyc-
erophosphocholine, phosphocholine, and phosphoethanolamine;
and Cho is a rate-limiting precursor in the synthesis of acetyl-
choline and a precursor of cell membrane phospholipids. These
water soluble choline-containing compounds are proxy indicators
of neuronal/glial cellular membrane turnover, and Cho levels are
related to cognitive functioning and Alzheimer’s disease (Chopra
et al., 2011; Tayebati and Amenta, 2013). Increased Cho con-
centration may be due to loss of cholinergic neurons and/or
increase in membrane phosphatidylcholine catabolism of neu-
ronal cells to provide free Cho for the subsequent deficiency in
acetylcholine production. In turn, membrane hypercatabolism
may affect neuronal connectivity and signal transduction, caus-
ing impaired membrane processing (Chopra et al., 2011; Tayebati
and Amenta, 2013).
Additionally, an increased N-acetyl aspartate (NAA) to total
Cr (tCr) ratio in the hippocampus has been observed in post-
menopausal women treated with low-dose HRT for more than
4 years compared to never-users, however, only among carri-
ers of the dementia-related risk ε4 allele of the apolipoprotein
E (ApoE) gene (Table 4) (Yue et al., 2007). NAA is a neuronal
marker reflecting neuronal density/function and/or mitochon-
drial metabolism; while tCR is mainly composed of phospho-
creatine (PCr) and creatine (Cr), which are associated with
high-energy phosphate metabolism, and constitute a marker for
phosphate metabolism. At normal conditions tCr concentra-
tion (Cr+PCr) in the brain is very stable, which is why it can
be used to normalize indexes, such as NAA/tCR. A decrease
of NAA indicates damage or reduction of neurons, whereas an
increase of NAA implies enhancement of the neuron metabolism
thus suggesting a positive effect of HRT on neuronal func-
tion and metabolism. Nonetheless, gene-by-hormonal interac-
tions have rarely been studied in relation to mental health in
menopause. In this case, genetic risk conferred by the ε4 allele
of the ApoE gene (Yue et al., 2007), which has a dose-related
effect on risk and onset age of AD, seems to interact with
HRT, and call for independent replication in larger samples.
Genetic markers associated with neurodegenerative disorders
might have interactive or addictive effects on hormonal shifts
effects.
All together these neurochemical changes provide initial evi-
dence of a beneficial effect of HRT on neuronal markers (Table 4).
No significant effect of HRT on the concentration of other neuro-
metabolites (e.g., myo-inositol, glutamate and glutamine) quan-
tified with MRS have so far been reported (Craig et al., 2007a; Yue
et al., 2007). Myo-inositol (ml) is a putative glial marker which
affects neuronal signal transduction and cellular osmolarity, and
increased mI has been found in neurodegenerative diseases; while
a decrease of the sum of glutamate plus glutamine (glx) has been
related to loss of glutamatergic neurons, reduced synthesis or
increased demand of glutamate as an amino acid.
BRAIN METABOLISM, RESTING STATE REGIONAL BLOOD FLOW AND
FUNCTIONAL CONNECTIVITY
Moreover, positron and single-photon computed emission
tomography studies of resting state brain activity indicated a
stimulating, or preserving, function of hormonal treatment for
the cerebral blood flow and connectivity (Table 5), however,
regions differing in cerebral glucose metabolism overlapped
poorly between studies (Ohkura et al., 1995; Eberling et al., 2000;
Maki and Resnick, 2000; Rasgon et al., 2001, 2005, 2014; Slopien
et al., 2003; Kenna et al., 2009). Nevertheless, it remains unclear
whether greater regional cerebral blood flow (rCBF) indicates bet-
ter performance. PET studies assessing the rCBF employ rCBF
as a marker of local neuronal activity; however questions remain
about the source and meaning of the rCBF, as other mechanisms,
such as changes in cerebrovascular response (vascular tone) must
also be considered. SPECT also measures rCBF, and is susceptible
to hemodynamic changes, since intra-cerebral vessels are respon-
sible for the rCBF and blood-brain barrier permeability; thus
increased blood flow may be attributed to effects of estrogen on
the cerebrovasculature (Ohkura et al., 1995; Eberling et al., 2000;
Maki and Resnick, 2000; Rasgon et al., 2001, 2005, 2014; Slopien
et al., 2003; Kenna et al., 2009). Finally, two recent studies of
women at high risk for Alzheimer’s disease provided evidence of
differential changes in brain metabolism depending on estrogen
formulation and/or estrogen-progestagen HRT (Silverman et al.,
2011; Rasgon et al., 2014).
Nonetheless, HRT related brain activity and connectivity
responses are not well elucidated (Table 5). In particular, so far
no studies of resting state MRI have been published. However,
lower mPFC-hippocampal connectivity at rest has been found
in healthy postmenopausal women at risk for dementia who use
HRT, in the presence of high plasma insulin levels (Kenna et al.,
2013). Thus, studies of reproductive aging and HRT, and their
relation with brain imaging of functional connectivity are needed.
EMOTION PROCESSING
The peri menopause is often accompanied by symptoms of
depression and anxiety (Al-Safi and Santoro, 2014), and stud-
ies of rodents and non-human primates have attempted to
investigate the neurobiology underlying postmenopausal-like
affective processing (Shively and Bethea, 2004; Mueller et al.,
2014). For instance, ovariectomized female rodents displayed
less anxiety-like behavior when receiving estradiol replacement
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(Mueller et al., 2014). In humans, increased stress-triggered nega-
tive mood after a three-month estrogen administration was noted
in healthy postmenopausal women (Newhouse et al., 2008), and
in older women (Dumas et al., 2012a). However, HRT has been
associated with decreased depressive symptoms in menopausal
women (Zweifel and O’Brien, 1997), though depending on psy-
chiatry history, age and study design; while other studies, such
as the Women’s Health Initiative study, provided conflicting evi-
dence (Henderson and Greicius, 2010). Moreover, free estradiol
levels were positively correlated with mood in a recent large study
of healthy women during early postmenopause (Henderson et al.,
2013), but again HRT, in particular current use, was associated
with symptoms of depression and anxiety in two large cohorts of
peri-menopausal women (Toffol et al., 2013), however estradiol
is generally recognized to have positive effects on mood (Soares,
2013).
Neuroimaging studies of emotion processing in menopausal
women are essentially lacking, and findings are thus far inconclu-
sive (Table 6). A randomized placebo-controlled cross-over study
including ten postmenopausal women portrayed an increased
activation, though in different regions, during negative emotional
stimuli processing, in both the placebo and estrogen-progestagen
treated groups, and higher activation of the left medial frontal
cortex during positive stimuli processing in the placebo group
(Love et al., 2010). Later, a larger cross-sectional study of long-
term HRT users also showed puzzling activation in estrogen
treated women and non-users, and in current vs. past HRT
users (Shafir et al., 2012). While Love et al. found no effect
on performance of the task (Love et al., 2010), Shafir et al.
found a slower response time in HRT users, but higher accu-
racy in picture rating among current users compared to past
users (Shafir et al., 2012). In addition, greater regional activ-
ity in the dorsal lateral prefrontal cortex during high conflict
resolution was found in one study investigating emotion regu-
lation in eleven peri- and postmenopausal women (Frey et al.,
2010).
Monoaminergic projections throughout the prefrontal and
parietal cortices are likely mediating the effect of estrogen and
progestagens on emotion and mood. Cortical and limbic struc-
tures are key regulators in emotion processing; principally the
dorsolateral prefrontal cortex, playing a role in the suppression
of emotion, was less activated during negative emotional stim-
uli in estrogen-progestagen treatment compared to placebo (Love
et al., 2010), and the amygdala, a key region in emotional learning,
had diminished emotion-induced activation after estrogen-only
treatment in the presence of dampened serotonergic function
(Epperson et al., 2012).
Interestingly, in relation to the “critical window” hypothesis,
are the results of a functional magnetic resonance imaging study
of older women, above the age of 65 years, comparing current
long-term HRT users vs. past short-term users, and fundamen-
tally indicating no difference in emotion-induced brain activity
(Pruis et al., 2009). To sum up, the precise alterations in neural
activity underlying the effects of HRT on mood in menopausal
women remain to be understood, since a quarter of heteroge-
neous neuroimaging studies is not sufficient neither to tackle the
question nor to draw conclusions.
TESTOSTERONE TREATMENT
Testosterone treatment in postmenopausal women has been
investigated by only one study. An fMRI study of nine post-
menopausal women indicated a decreased activation of frontal
and lingual gyri during verbal fluency, and of the parietal lobe and
precuneus during mental rotation, after 6 months of transder-
mal testosterone treatment (Davis et al., 2013). Higher endoge-
nous testosterone has been associated with superior performance
in verbal fluency, and spatial and mathematical abilities; thus
these preliminary results might indicate a more efficient brain
functioning in response to cognitive tasks.
Testosterone levels are about 65% lower during menopause,
and though ovarian production of testosterone continues after
natural menopause, very low levels are gradually reached.
Testosterone treatment is generally used for menopausal women
with female sexual dysfunction, i.e., diminished sexual interest.
Thus, knowledge of effect of testosterone replacement therapy
in the brain should also be achieved, although it also remains
to be established if putative effects are directly attributable to
testosterone or rather due its conversion to estradiol, as has been
showed convincingly for e.g., the 5-HT2A receptor responses to
HRT (Sumner and Fink, 1998).
DISCUSSION
Menopause is the most influential biological and health-related
event for most middle-aged women. During the perimenopause
(Harlow et al., 2012), which can last several years, the level
of estrogen fluctuates substantially but gradually declines. The
lowered estrogen levels are often accompanied by sometimes
debilitating vasomotor symptoms (Harlow et al., 2012; Al-Safi
and Santoro, 2014). The decision to use HRT or not represents
a major concern for afflicted women and their clinicians. Effects
of the menstrual cycle and pharmacological contraceptive treat-
ment on the central nervous system, inferred from behavioral
and neurophysiological activity changes in response to cognitive
and emotional stimuli, indicate a role of estrogen and proges-
terone on brain function in healthy fertile women (Mueller et al.,
2014; Toffoletto et al., 2014). Alike, menopausal hormone changes
are likely to modulate neuronal activity and contribute to age-
related memory loss as well as the development of disorders such
as dementia or major depression (Tables 1–6).
It is tempting to conclude that the present findings reflect true
alterations in neural activity in the face of a hormonal pertur-
bation (Tables 1–6). However, the interpretation of the results
presented in this review remains a matter of debate, since less
activation during task performance can be interpreted either as a
more efficient use of neuronal resources or as an impaired state
in which adequate activation of resources cannot be executed.
Vice versa, higher activation can be interpreted as beneficial, or
imply a compensatory response, or a less efficient use of resources
(Henderson and Greicius, 2010). Interestingly, most of the effects
were observed after a relatively brief time of HRT use. Thus, the
optimal duration, or dose of HRT, or timing of treatment start,
necessary to maintain a premenopausal cerebral state or to trigger
neuroplasticity in mature women, is unknown.
Peri- and postmenopause are marked not only by vasomotor
symptoms, but also by cognitive and emotional complaints that
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affect quality of life and overall functioning; however the degree
to which the decline in estrogen and/or progesterone production
is responsible is not yet clear. Increasing evidence from obser-
vational and HRT studies of postmenopausal women supports
the influence of ovarian hormones on cognition and mood both
at the behavioral and neural level, although it remains ambigu-
ous whether this influence is positive or harmful (Henderson and
Greicius, 2010). In the reviewed studies, estrogen altered the acti-
vation of brain structures underlying memory performance, par-
ticularly the fronto-cingulate region; however there appears to be
a puzzling dissociation between neuropsychological performance
and neural activity, since many studies that found a hormonal-
dependent effect in neuroimaging data did not observe neuropsy-
chological alterations across hormonal conditions (Tables 1–3).
Also, cerebral activity changes are task-dependent, as shown by
experimental models (Sherwin and Henry, 2008; Gibbs, 2010),
and may as well be biased by differences in education and health
of the women. Longitudinal observations are hence indispens-
able to identify if, and at which critical age, the metabolic decline
may become appreciable (Henderson and Greicius, 2010). Thus,
abnormal activation when associated with normal task perfor-
mance may reflect compensatory cerebral metabolic activity in
response to a subtle/subclinical loss of cognitive capacity, and
precede cognitive impairment in individuals at increased risk for
neurodegenerative and psychiatric disorders. However, an alter-
native explanation to group differences in activation patterns
during memory processes may be that postmenopausal women
activate a distinct cognitive network. Overall, it seems plausi-
ble to conclude that estrogen, alone or in combination with
progestagens, positively affects brain activation during memory
processing in postmenopausal women (Tables 1, 2), likely via
interactions with basal forebrain cholinergic projections (Gibbs,
2010). This suggestion is also in line with findings of preserved
visual memory in ovariectomized monkeys treated with estrogen,
alone or in combination with progesterone, compared to placebo-
treated ovariectomizedmonkeys (Voytko et al., 2009). In contrast,
results regarding cerebral functional responsiveness to emotional
stimulation are lacking and far from being consistent (Table 6).
Furthermore, studies of neurochemical pathways have pin-
pointed the cholinergic, serotonergic, and dopaminergic sys-
tems as biological mediators of estrogen influences on the brain
(Table 4). Cholinergic and monoaminergic wide-spread projec-
tions to prefrontal cortical regions interactively mediate several
functions ranging from working memory to emotion processing.
For instance, quantitative and qualitative differences in density of
axons immunoreactive to ChAT, dopamine ß-hydroxylase, tyro-
sine hydroxylase and serotonin in the dorsal medial prefrontal
cortex was found in ovariectomized monkeys compared to con-
trol animals, and following 1month treatment with estrogen-only
or estrogen-progesterone (Kritzer and Kohama, 1998, 1999). The
interplay between these neurotransmitter systems is of relevance
for schizophrenia and depression, two mental disorders charac-
terized by sex differences in their occurrence, and their interaction
with hormonal changes is likely to impact treatment response.
More, knowing that cerebral blood flow decreases with age,
positron, and single-photon computed emission tomography
studies suggested a preservative/stimulating function of estrogen
for the cerebral blood flow (Table 5). In view of these findings
(Tables 1–5), and of studies of monkeys (Voytko et al., 2009),
a putative neuroprotective role of estrogen in neuronal integrity
maintenance and cognitive function preservation against regional
cerebral metabolic decline could thus be anticipated/predicted,
also considering meta-analytical findings reporting an effect of
about one-third reduction in the risk of Alzheimer’s disease
among HRT users (Yaffe et al., 1998; Hogervorst et al., 2000;
LeBlanc et al., 2001; Nelson et al., 2002). However, as highlighted
by the Women’s Health Initiative project, timing is likely to be
critical for positive HRT effects on cognition (Henderson and
Greicius, 2010).
Of special interest in relation to neurogenesis and synap-
tic plasticity is the hippocampus, a crucial region in memory
and learning (Gibbs, 2010). Preclinical research has highlighted
several effects of estrogen on structure and function of the hip-
pocampus in animal experiments, also via effects on choliner-
gic projections from the forebrain, ranging from neurotrophic
to neuroplastic to neurobehavioral effects (Voytko et al., 2009;
Wnuk et al., 2012; Daniel, 2013). The hippocampus is atro-
phied and functionally impaired in Alzheimer’s disease and in
the presence of a history of repeated depressive episodes, neuro-
biological features which are linked to cognitive function. Larger
hippocampal volume in HRT users has been indicated by mag-
netic resonance imaging studies, with the first evidence reported
by Eberling et al. (2003). Several experimental and clinical stud-
ies have in fact provided evidence of a positive modulatory effect
of estrogen use on hippocampal anatomy, though aversive or
absent effects have also been reported (Erickson et al., 2005, 2010;
Boccardi et al., 2006; Lord et al., 2008; Espeland et al., 2009;
Wnuk et al., 2012). Discordance of the findings and lack of lon-
gitudinal randomized controlled trials leaves room for equivocal
conclusions on the effects of HRT on hippocampus morphology.
However, several neuroimaging studies indicated an enhancing
effect of HRT on hippocampus function (Maki and Resnick,
2000; Robertson et al., 2001; Gleason et al., 2006; Norbury et al.,
2007; Berent-Spillson et al., 2010; Maki et al., 2011; Smith et al.,
2011; Shafir et al., 2012), suggesting potential positive estrogen-
mediated effects on neuronal survival and plasticity through the
cholinergic system (Daniel, 2013). Thus hippocampal, together
with prefrontal cortical, function is a strong candidate substrate
mediating the hormonal effects on cognition.
Estrogens interact with neuronal networks at many levels and
affect brain development and aging (Sherwin and Henry, 2008).
The modulation by estrogen may therefore account for hormonal
regulation of cognition and mood, as for instance women have
increased risk for developing Alzheimer’s dementia and major
depression compared to men, but the pathophysiological mech-
anisms behind these differences are unknown (Henderson and
Greicius, 2010). Non-invasive measurement of brain function
through neuroimaging techniques is advantageous compared to
traditional behavioral measures. The BOLD signal and the rCBF
are proxy outcomes, endpoints which can be objectively mea-
sured and are potentially related to a clinical phenotype, such as
working memory (Henderson and Greicius, 2010). Biological rel-
evance could thus be inferred by the effect of HRT on neuronal
activity; consequently the question whether certain intermediate
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phenotypes can be classified as endophenotypes (Lenzenweger,
2013) for neurodegenerative and psychiatric disorders occurring
during menopause remain to be addressed. Neuroimaging genet-
ics of the peri- and postmenopause and HRT use is required
to provide knowledge about constitutional vulnerability to hor-
monal changes in relation to mental health (e.g., the first neu-
roimaging genetic study of premenstrual dysphoric disorder,
Comasco et al., 2014), as well as molecular research will be essen-
tial to elucidate epi-genotype-mediated mechanisms. To date
there is a lack of focus on genetic correlates of menopausal hor-
monal effects, with only four studies having considered the ApoE
genotype (Rasgon et al., 2001, 2005; Robertson et al., 2001; Yue
et al., 2007). For instance polymorphisms in the estrogen receptor
alpha and beta genes (ESR1 and ESR2) have been associated with
cognitive impairment in old women in two large longitudinal
studies (Yaffe et al., 2002, 2009), but their potential intermedi-
ate neuronal correlates have not been investigated. Additionally,
the modulatory association between the catecholamine degrad-
ing enzyme catechol-O-methyltransferase (COMT) and dorso
and ventro lateral prefrontal cortex and supragenual anterior
cingulate cortex activation during working memory has been
demonstrated in schizophrenia (Rasetti and Weinberger, 2011),
but remains to be explored in relation to menopausal cognitive
decline.
Future studies will thus need to investigate whether puta-
tive intermediate phenotypes are involved in the causal pathway
between genes and psychopathology, besides having a mere asso-
ciative or consequential relationship with the illness, as well as
the heritability of the endophenotype(s) (Lenzenweger, 2013).
By means of such approach, differences between statistical vs.
biological significance can be further discerned.
Widespread classical nuclear (i.e., estrogen receptor α and β,
progesterone receptor A and B), and non-classical membrane-
associated (e.g., G protein-coupled estrogen receptors and the
progesterone receptor membrane component 1), receptors are
targeted by estradiol and progesterone, thus mediating their
effects on brain structure as well as cognitive-affective processing
(Brinton et al., 2008; Wharton et al., 2012). Remarkably, estrogen
replacement treatment has been the most studied (Tables 1–6),
even though it is far less often used compared to combined
estrogen-progestagen treatment. Estrogen-only treatment is
prescribed only for hysterectomized women, as the progestagen
addition is needed for protection against endometrial hyperplasia
and cancer. Moreover, two recent studies of women at high risk
for Alzheimer’s disease provided evidence of differential changes
in brain metabolism depending on estrogen formulation and/or
estrogen-progestagen HRT (Silverman et al., 2011; Rasgon et al.,
2014). Lately, a study found a positive correlation between
serum progesterone, but not estrogen, levels and verbal memory
and global cognition in healthy women during the early post-
menopause (Henderson et al., 2013). Thus, potential cumulative
neuroprotective or counteracting effects of progestagens—
via its metabolites or indirectly via type-A γ-aminobutyric
acid receptor signaling modulation—still need to be
elucidated.
Importantly sampling differences between the studies also
need to be considered since a gynecological clinic-based sample
(e.g., women who underwent oophorectomy with or without
hysterectomy, i.e., surgical menopause) is likely to differ from
a sample of asymptomatic healthy menopausal women (Rocca
et al., 2014). Furthermore, natural menopause is typified by a
gradual decline of estradiol and androgen levels until circulat-
ing levels are exclusively maintained by peripheral conversion
of adrenal steroids (Harlow et al., 2012; Al-Safi and Santoro,
2014). On the contrary, surgical menopause causes a dras-
tic and complete cessation of both estradiol and testosterone
secretion. Finally, efforts to stage reproductive aging according
to standardized nomenclature and classifications, as the Stages
of Reproductive Aging Workshop (STRAW) criteria, should be
made to facilitate comparisons between studies (Harlow et al.,
2012).
Hormonal supplementation in peri- and postmenopausal
women remains a source of great health concern. The so-called
“window of opportunity” or “critical period” hypothesis can-
not be rejected based on the present results, but it is expectable
that timing of HRT (i.e., age and proximity to menopause when
HRT is initiated) will imply a different brain response, and that
chronological and reproductive aging matter too (Henderson and
Greicius, 2010; Daniel, 2013; Maki, 2013; Rocca et al., 2014). A
critical threshold below which the function of neurobiological
systems remains impaired by loss of ovarian function and cannot
be triggered by exogenous hormonal supplementation is indeed
plausible.
CONCLUSIONS
Questions to-be-answered:
I. What are the neurobiological mechanisms underlying
menopause hormonal transition and HRT effects in the
brain?
II. Are there synergistic or counteracting effects of estrogen
together with progestagens and/or androgens?
III. Which dosage and combination of HRT should be prescribed?
IV. If and when should HRT be initialized and terminated to be
most efficient in optimizing women’s mental health?
Collectively, neuroimaging studies indicate altered brain activa-
tion patterns by estrogen-only or estrogen-progestagen treatment
in therapeutic doses in postmenopausal women, corroborating
preclinical findings of effects of estrogen on neural structure
and function in mature animals. These results call for further
well-powered randomized-controlled multi-modal neuroimag-
ing studies, using a battery of standardized neuropsychological
tests, as well as for complementary investigation on the corre-
lated molecular mechanisms of reproductive aging and HRT in
preclinical models.
KEY CONCEPTS
• Menopausal transition: period in a women’s life lasting sev-
eral years around the age of fifty where ovarian hormone
levels, estrogens and androgens, fluctuate and decrease until
menopause occurs with the termination of the menstrual cycle,
and post-menopause is established; this physiological transi-
tional hormonal change (peri-menopause), as well as surgically
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induced menopausal transition, are of relevance to the aging
female brain.
• Hormonal replacement therapy (HRT): exogenous supple-
mentation of estrogen and/or progesterone given during peri-
menopause to treat vasomotor symptoms. The potential pro-
tective and/or aversive effects, and the biological mechanism of
action of HRT, as well as the effects of interrupting HRT, on
cognitive and emotional functioning remain largely elusive.
• Window of opportunity: crucial period of time spanning from
peri- to post-menopause during whichHRT could be used with
beneficial effects on women’s physical and mental health.
• GnRHa hormone manipulation: treatment with a
gonadotropin releasing hormone agonist that initiates a
biphasic response, which initially stimulates ovarian sex-
steroid hormone production and subsequently induces a
pharmacological pseudo-menopausal state, which is estab-
lished by the second to fourth week of administration, with a
complete cessation of both estradiol and testosterone secre-
tion. It provides a model of early menopause and menopausal
transition.
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APPENDIX
ACRONYMS/ABBREVIATIONS IN THE TABLES
aC: anterior cingulate; aCC: anterior cingulate cortex; AChE:
acetylcholinesterase; BS: brain stem; Cau: caudate; Cb: cerebel-
lum; CEE: conjugated equine estrogen; CER: cerebellar cortex;
CG: cingulate gyrus; Cn: caudate nucleus; Cun: cuneus; daCC:
dorsal anterior cingulate cortex; dlFC: dorsolateral frontal cor-
tex; dFG: dorsal frontal gyrus; dlPFC: dorsolateral prefrontal
cortex; EC: entorhinal cortex; E: estrogen; FC: frontal cortex;
FDG: fluorodeoxyglucose; FG: frontal gyrus; FL: frontal lobe; FP:
follicular phase; FuG: fusiform gyrus; gr: group; HC: hippocam-
pus; HERA: hemisphere encoding retrieval assimetry; HG: hip-
pocampal gyrus; HMPAO: hexamethylpropylene-amino oxime;
HT: hormonal treatment (E+P); Hy: hypothalamus; iF: infe-
rior frontal; iFC: inferior frontal cortex; iFG: inferior frontal
gyrus; Ins: insula; ipFG; inferior posterior frontal gyrus; iPL:
inferior parietal lobe; iTG: inferior temporal gyrus; iTL: infe-
rior temporal lobe; LgG: lingual gyrus; Ln: lentiform nucleus;
lOFC: lateral orbito frontal cortex; mAChR: muscarinic acetyl-
choline receptors; MB: mammillary body; MF: medial frontal;
mesial-TR: mesial temporal region; mFC: medical frontal cortex;
meFG: medial frontal gyrus; meOFC: medial orbitofrontal cor-
tex; meOG: medial occipital gyrus; miF: middle frontal; miFG:
middle frontal gyrus; mFL: medial frontal lobe; miTG: mid-
dle temporal gyrus; MP: menopause; n: number of individuals;
Neg: negative pictures; Neu: neutral pictures; NT: no treat-
ment; OC: occipital cortex; oF: orbital frontal; OFC: orbitofrontal
cortex; OL: occipital lobe; P: progesterone/progestins; pC: pos-
terior cingulate; PC: parietal cortex; pCC: posterior cingulate
cortex; PCL: paracentral lobule; pgG: postcentral gyrus; pCun:
precuneus; paracL: paracentral lobule; PHG: parahippocampal
gyrus; PL: parietal lobe; pgACC: pregenual anterior cingulate
cortex; pIns: posterior insula; pCG: posterior cingulate gyrus;
PFC: prefrontal cortex; PL: parietal lobe; Pos: positive pictures;
post-cG: postcentral gyrus; pPHG: posterior para-hippocampal
gyrus; pre-cG: precentral gyrus; Pu: putamen; rCMRglc: regional
cerebral glucose metabolism; sF: superior frontal; sFG: supe-
rior frontal gyrus; smG: supra-marginal gyri; sPC: superior
parietal cortex; sTG: superior temporal gyrus; STRAW: Stages
of Reproductive Aging Workshop [ranging from −5 to +2]
(Harlow et al., 2012); TC: temporal cortex; TD: tryptophan
depletion; thal: thalamus; TL: temporal lobe; TP: temporal pole;
TR: temporal region; VAChT: vesicular acetylcholine transporter;
vlPFC: ventrolateral prefrontal cortex; vpTL: ventral posterior
temporal lobe.
¤SEM: standard error of the mean.
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